|
PKC412 restores functionality of the keratin cytoskeleton in the skin disorder epidermolysis bullosa simplex
Invention Summary:
Epidermolysis bullosa simplex (EBS) is a highly penetrant genetic condition that causes fragility of skin keratinocytes resulting in fluid-filled skin blisters that erode upon scratching or minor pressure on the skin. There is no good cure for EBS, and treatment typically involves preventive and/or supportive care...
Published: 6/6/2023
|
Inventor(s): Bishr Omary, Thomas Magin, Jacques Roberge, Katrin Rietscher, Pei Li
Keywords(s): Dermatology
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Rare Disease
|
|
Novel Selective Anti-chlamydial Compounds and Use
ze: 12px;color: #4F81BD;line-height: 1;border-collapse: collapse; }
A set of photographs showing inhibition of C. trachomatis by acylpyrazoline (Using compound 4)
Invention Summary:
Chlamydia trachomatis is the most common sexually transmitted pathogenic bacterium worldwide. If left untreated...
Published: 1/31/2024
|
Inventor(s): Huizhou Fan, Jacques Roberge
Keywords(s): Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Novel Ricin Inhibitors
(A) Model showing the interaction of Ricin toxin A (RTA) with the P stalk to access the sarcin/ricin loop (SRL) of the eukaryotic ribosome. 26S rRNA and 60S subunit are shown in light gray and dark gray, respectively. (B) The 50% inhibitory concentration (IC50) of fragments against RTA.
Invention Summary:
Ricin toxin is lethal to human at small doses,...
Published: 4/21/2024
|
Inventor(s): Nilgun Tumer, Xiao-Ping Li, Jacques Roberge, David Augeri, Bin Cao, Anastasiia Tsymbal
Keywords(s): Drug Discovery/Screening
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
A New Method to Treat Asthma and Allergic Reaction
PBS PeptideIntranasal peptide treatment inhibits ILC2-dependent mucus productionInvention Summary:Although most patients with asthma respond to regular inhaled glucocorticoid (corticosteroid) therapy, 5% to 25% of people with asthma have more severe disease and do not respond...
Published: 4/21/2024
|
Inventor(s): Mark Siracusa, Jacques Roberge
Keywords(s): Autoimmune, Peptides, Respiratory Disease
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
